Allarity Therapeutics, Inc.

ALLR · Nasdaq · United States

Share price · ALLR

$0.87-0.48 (-35.41%) 3M

close as of 2026-11-18 · 24h delayed · vol 291K (2.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ALLR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 3 Nov 2026+15.6%
  2. 2 Nov 2026+12.3%
  3. 16 Oct 2026+7.5%

    Nothing announced by ALLR that day or the session before.

  4. 12 Oct 2026-13.1%
  5. 30 Sep 2026+8.8%
  6. 22 Sep 2026-5.1%

    Nothing announced by ALLR that day or the session before.

  7. 8 Sep 2026-12.0%

    Nothing announced by ALLR that day or the session before.

  8. 5 May 2026+12.0%

    Nothing announced by ALLR that day or the session before.

  9. 21 Apr 2026+10.4%
  10. 10 Apr 2026+10.4%

    Nothing announced by ALLR that day or the session before.

Share of unusual movement by asset

For each asset, the share of ALLR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
stenoparib
events and moves
94%
Other company news (earnings, financing, releases naming no asset)—25%
Sessions with no dated event—71%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
PARP1/2 · Tankyrase 1/2Small molecule
Ovarian Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
March 2027 (1)
stenoparibPhase 2Advanced Ovarian Cancer
Est. primary completion 2027-03 · NCT03878849 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3<$0.1M$4.2M—$6.2M-$2.9M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$1.4M$27M$3.4M-$2.6M operating cash flowreport ↗
2026-Q1<$0.1M$1.3M$30M$2.8M-$4.5M operating cash flowreport ↗
2025-Q3—$1.2M$17M$2.8M-$3.4M operating cash flowreport ↗
2025-Q2—$2.3M$18M$2.3M-$5.5M operating cash flowreport ↗
2025-Q1$0$1.4M$28M$2.7M-$2.7M operating cash flowreport ↗
2024-Q3—$1.0M$19M$12M-$5.4M operating cash flowreport ↗
2024-Q2—$1.1M$19M$1.6M-$7.2M operating cash flowreport ↗
2024-Q1—$2.2M—$3.8M-$1.5M operating cash flowreport ↗
2023-Q3—$1.9M—$4.5M-$5.4M operating cash flowreport ↗
2023-Q2—$1.1M$0.4M$2.4M-$2.5M operating cash flowreport ↗
2023-Q1—$1.4M$0.3M$3.4M-$3.2M operating cash flowreport ↗
2022-Q3—$3.0M$4.0M$5.0M-$4.4M operating cash flowreport ↗
2022-Q2—$1.7M$7.7M$5.1M-$4.2M operating cash flowreport ↗
2022-Q1—$1.3M$15M$3.1M-$5.8M operating cash flowreport ↗
2021-Q3—$1.6M$5.6M$1.4M-$2.9M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0.3M$6.6M$15M$2.8M-$15M operating cash flowreport ↗

For FY2025, Allarity Therapeutics reported revenue of $0.32M (2024: $0M), R&D spend of $6.6M, up 8.2% YoY, and cash and equivalents of $14.7M. The company recorded a net loss of $11.23M and reported a quarterly net burn of $11.23M.

Allarity remains focused on stenoparib and its DRP companion diagnostic. A new clinical protocol in platinum-resistant ovarian cancer began enrollment in June 2025, and a randomized stenoparib-plus-temozolomide trial in relapsed small cell lung cancer opened in January 2026 with funding from the U.S. Department of Veterans Affairs. The reported revenue came from laboratory service agreements, and other legacy product candidates were terminated.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$6.1M$20M$6.1M-$17M operating cash flowreport ↗
2023-FY—$7.1M$0.2M$3.0M-$13M operating cash flowreport ↗
2022-FY—$6.9M$2.0M$4.0M-$17M operating cash flowreport ↗
2021-FY—$14M$20M$6.7M-$15M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-30Graff Jeremy R. · See RemarksOption exercise39,494——Form 4
2026-09-30Graff Jeremy R. · See RemarksTax withholding14,613$0.97$14KForm 4
2026-09-30Graff Jeremy R. · See RemarksOption exercise (derivative)39,494——Form 4
2026-01-28Jensen Thomas · CEOAward / grant200,000——Form 4
2026-01-28McLaughlin Gerald W. · directorAward / grant45,000——Form 4
2026-01-28Ervin Jeffrey S · CFOAward / grant150,000——Form 4
2026-01-28Graff Jeremy R. · See RemarksAward / grant133,333——Form 4
2026-01-22Graff Jeremy R. · See RemarksOption exercise48,147——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 14 reporting institutions held 1.0M shares ($1.0M, 6.0% of shares outstanding).

#InstitutionSharesValue
1RENAISSANCE TECHNOLOGIES LLC228,084$249K
2GEODE CAPITAL MANAGEMENT, LLC190,393$208K
3VANGUARD CAPITAL MANAGEMENT LLC171,795$187K
4STATE STREET CORP137,600$150K
5VANGUARD FIDUCIARY TRUST CO74,913$82K
6NORTHERN TRUST CORP48,103$52K
7XTX Topco Ltd28,967$32K
8TWO SIGMA INVESTMENTS, LP27,492$30K
9UBS Group AG23,158$25K
10TWO SIGMA SECURITIES, LLC12,334$13K
11CITIGROUP INC7,766$8K
12JONES FINANCIAL COMPANIES LLLP1$1
13DANSKE BANK A/S1$1
14Caitong International Asset Management Co., Ltd1$1